Skip to main content
. 2023 Mar 20;14:49. doi: 10.1186/s13244-023-01391-z

Table 3.

PI-RADSv2.1 and PI-RADSv2 scores assigned by the three groups of readers

Benign lesions & ISUP 1 cancers csPCas
Experienced seniors Less experienced seniors Juniors Experienced seniors Less experienced seniors Juniors
Predefined lesions (N = 240) PI-RADSv2.1 1 4 [2–12] 4 [1–5] 8 [2–9] 1 [0–2] 1 [0–1] 1 [0–1]
2 49 [20–61] 20 [14–39] 22 [19–52] 5 [3–6] 0 [0–2] 4 [2–9]
3 24 [18–29] 15 [12–18] 33 [28–34] 5 [4–7] 4 [3–6] 8 [3–11]
4 65 [44–86] 96 [90–111] 73 [56–95] 35 [34–39] 39 [38–41] 35 [34–39]
5 11 [8–15] 13 [11–20] 15 [10–24] 32 [28–36] 33 [30–35] 32 [26–35]
PI-RADSv2.0 1 3 [1–10] 2 [1–3] 2 [1–7] 1 [0–3] 0 [0–0] 0 [0–1]
2 28 [17–41] 23 [12–24] 21 [12–23] 3 [2–5] 1 [0–4] 2 [1–3]
3 26 [21–32] 16 [12–18] 38 [29–44] 5 [5–7] 3 [2–4] 10 [3–12]
4 87 [49–97] 105 [100–112] 78 [71–97] 38 [34–40] 40 [38–43] 41 [37–42]
5 11 [9–15] 13 [11–19] 15 [11–24] 32 [28–36] 34 [31–35] 32 [26–35]
Per-lobe analysis (N = 318) PI-RADSv2.1 1 71 [7–78] 49 [8–58] 50 [22–57] 4 [0–7] 1 [0–3] 4 [2–6]
2 57 [48–60] 49 [21–75] 40 [37–61] 5 [4, 5] 3 [2–7] 4 [2–5]
3 33 [22–33] 17 [14–18] 37 [32–47] 5 [3–6] 5 [2–10] 8 [3–10]
4 60 [46–88] 99 [89–108] 77 [58–96] 36 [32–39] 37 [37–39] 36 [35–38]
5 18 [11–23] 15 [12–23] 19 [15–35] 43 [36–49] 42 [39–44] 43 [35–49]
PI-RADSv2.0 1 1 [0–2] 1 [0–2] 1 [0–3] 0 [0–1] 0 [0–0] 0 [0–1]
2 107 [77–114] 82 [63–89] 65 [58–83] 6 [5–11] 7 [5–9] 6 [4–8]
3 31 [22–39] 15 [11–23] 37 [28–51] 5 [3–6] 3 [2–4] 8 [3–10]
4 79 [54–101] 106 [102–112] 81 [72–98] 39 [31–41] 38 [36–41] 38 [36–40]
5 18 [11–24] 15 [12–22] 19 [15–35] 43 [36–49] 42 [42–46] 43 [36–49]

Data are presented as median number of lesions/lobes [interquartile range]

N Number of lesions/lobes, csPCas Clinically significant prostate cancers, ISUP International society of urological pathology, PI-RADS prostate imaging-reporting and data system